WHO recommends combinations of an artemisinin derivative plus an antimalarial drug of longer half-life as treatment options for uncomplicated Plasmodium falciparum infection. In Africa, artemether–lumefantrine is the most widely used artemisinin-based combination therapy, whereas artesunate–mefl oquine is used infrequently because of a perceived poor tolerance to mefl oquine. WHO recommends reconsideration of the use of artesunate– mefl oquine in Africa.